
The Health, Labor and Welfare Ministry
16:56 JST, March 7, 2023
TOKYO (Jiji Press) —Japan will start COVID-19 vaccinations for fiscal 2023 on May 8 for people at high risk of developing severe symptoms, a health ministry expert panel said Tuesday.
For the year that starts next month, people aged 65 or older and those with underlying conditions will have the opportunity to receive two COVID-19 vaccine shots between May and December, the panel said.
The current vaccination program for those aged 12 or older and not included in the high-risk groups will end on May 7. Between September and December, they will be allowed to receive one shot, according to the panel.
Vaccinations will remain free. Beyond fiscal 2023, recipients may have to partially pay the costs.
For 6-month- to 11-year-olds, vaccinations will remain available anytime.
"Society" POPULAR ARTICLE
-
Japan’s Maglev Shinkansen’s Partially Completed Station Unveiled; Station Will Be Only Underground Stop Between Shinagawa, Nagoya
-
Fukuoka City School Lunch Menu with Only One Karaage Fried Chicken Draws Criticism; Mayor Vows to Improve School Meals
-
2025 Expo Osaka : Expo Venue Hit by Swarms of Chironomids; Organizers Cooperating with Pest Control Companies, Others to Deal with Outbreak
-
Japanese Students at Harvard Worried by U.S. Move; 260 at Harvard Part of 13,500 Japanese Students in U.S.
-
Japanese Swords Banned from Tourist Programs, Putting Damper on the ‘Samurai Experience’
JN ACCESS RANKING
-
Aichi Rice Production Under Siege from Warming Climate; Record Heat Stunts Crop Growth, Causes Greater Pest Activity
-
Japanese Researchers Develop ‘Transparent Paper’ as Alternative to Plastics; New Material Is Biodegradable, Can Be Produced with Low Carbon Emissions
-
Trump: Nippon Steel Will Part Own U.S. Steel, U.S. to Be in Control; Share Distribution, Other Details Remain Unclear
-
Japan’s Core Inflation Hits More than 2-year High, Could Force Year-End BOJ Hike
-
Japan’s Cooperation in Alaska LNG Development Project Emerges in Japan-U.S. Tariff Negotiations; But Industry Concerns Exist